



Correction to: RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

Grzegorz S. Nowakowski¹ · Dok Hyun Yoon² · Patrizia Mondello³ · Erel Joffe³ · Anthea Peters⁴ · Isabelle Fleury⁵ · Richard Greil⁶ · Matthew Ku⁷ · Reinhard Marks⁸ · Kibum Kim^{9,10} · Pier Luigi Zinzani^{11,12} · Judith Trotman¹³ · Lorenzo Sabatelli¹⁴ · Eva E. Waltl¹⁵ · Mark Winderlich¹⁵ · Andrea Sporchia¹⁵ · Nuwan C. Kurukulasuriya¹⁶ · Raul Cordoba¹⁷ · Georg Hess¹⁸ · Gilles Salles³

Published online: 11 July 2023
© The Author(s) 2023

Correction to: Annals of Hematology

<https://doi.org/10.1007/s00277-023-05196-4>

Following the online publication of this paper, the authors have learned that the National Comprehensive Cancer Network (NCCN) requires some editorial changes relating to how their guidelines are referenced within the paper.

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source,

The original article can be found online at <https://doi.org/10.1007/s00277-023-05196-4>.

✉ Grzegorz S. Nowakowski
Nowakowski.Grzegorz@mayo.edu

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA

² Department of Oncology, Asan Medical Center, Songpa-gu, Seoul, South Korea

³ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

⁴ Department of Oncology, University of Alberta, Edmonton, AB, Canada

⁵ Maisonneuve-Rosemont Hospital, Institute of Hematology, Oncology and Cell Therapy, Montreal University, Montreal, Canada

⁶ Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-CCCIT, and Cancer Cluster Salzburg, Salzburg, Austria

⁷ Department of Haematology, St Vincent's Hospital and University of Melbourne, Melbourne, VIC, Australia

⁸ University Hospital Freiburg Internal Medicine I, Freiburg im Breisgau, Germany

⁹ University of Utah, Salt Lake City, UT, USA

¹⁰ University of Illinois at Chicago, Chicago, IL, USA

¹¹ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto Di Ematologia "Seragnoli", Bologna, Italy

¹² Dipartimento Di Medicina Specialistica, Diagnostica E Sperimentale, Universita Di Bologna, Bologna, Italy

¹³ Haematology Department, Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia

¹⁴ Incyte Biosciences International Sarl, Morges, Switzerland

¹⁵ MorphoSys AG, Planegg, Germany

¹⁶ MorphoSys AG, Boston, MA, USA

¹⁷ Department of Hematology, Fundacion Jimenez Diaz University Hospital, Health Research Institute IISFJD, Madrid, Spain

¹⁸ Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg-University Mainz, Mainz, Germany

provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will

need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.